HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage compa...
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleas...
TORONTO and CHICAGO, March 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (*Medexus*) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it...
TORONTO and CHICAGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (*Medexus*) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the...
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...